+65 3158 9940
1300 798 820
+64 9801 0299
Melbourne, Australia and Singapore, 23 December 2016: An international study has found that women with metastatic triple-negative breast cancer (mTNBC) demonstrated improved progression-free survival when treated with a combination of ABRAXANE (nanoparticle albumin-bound paclitaxel) and carboplatin, compared to other chemotherapy combinations.
Charleston, South Carolina and Singapore, October 12, 2016: Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the “Company”) and Specialised Therapeutics Asia (“STA”) today announced the signing of an exclusive license agreement for the Company’s lead investigational anti-cancer compound, Zoptrex™ (zoptarelin doxorubicin), for the territories of Australia and New Zealand (the “Territory”). Zoptrex™, a novel synthetic
Melbourne, Australia 16 June 2016: International biopharmaceutical company Specialised Therapeutics Australia has struck an important agreement with global logistics partner World Courier Australia (WCA) to manage and handle its growing portfolio of specialist healthcare products around the country.
Singapore, Madrid and Melbourne, Australia, 31 March 2016: International biopharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST Asia) will seek regulatory approvals for novel multiple myeloma drug Aplidin® (plitidepsin) following the release of positive results in a pivotal Phase 3 study.
Melbourne, Australia, 7 March 2016: Specialized Therapeutics Pty Ltd and Mundipharma Pty Limited today announce a sublicense agreement enabling Mundipharma to assume all commercialisation responsibilities for the anti-emetic products ALOXI® (palonosetron hydrochloride) and AKYNZEO® (netupitant/palonesetron). Under the terms of the arrangement, Specialized Therapeutics grants Mundipharma exclusive marketing, promotion, distribution and sales rights for the anti-nausea and vomiting pharmaceutical
MELBOURNE, Australia, REDWOOD CITY, Calif, USA and GENEVA, Switzerland, 29 September 2015: Specialised Therapeutics Australia and Genomic Health announce the presentation of the first results1 from the Trial Assigning IndividuaLised Options for Treatment (Rx), or TAILORx, a large, prospectively conducted trial, designed and conducted by the ECOG-ACRIN Cancer Research Group under the sponsorship of the U.S. National Cancer Institute (NCI). The study, published online in
Melbourne, Australia, 17 September 2015: A NOVEL drug which helps neurosurgeons to better visualise and remove malignant brain tumours has been approved for marketing and distribution in New Zealand by Medsafe. The drug, GLIOLAN (aminolevulinic acid HCl), assists neurosurgeons to better visualise and more completely remove malignant brain tumours (gliomas) by causing them to become
Melbourne, Australia, 3 September 2015: A BREAKTHROUGH genetic test that could spare thousands of Australian women with early stage breast cancer from chemotherapy and its toxic side effects will be considered for reimbursement later this year. The multi-gene test, known as the Oncotype DX® Breast Cancer Assay, predicts a patient’s likely benefit from chemotherapy and the overall risk
Melbourne, Australia, 20 August 2015: Australian biopharmaceutical company Specialised Therapeutics Australia has struck an exclusive license and commercialisation agreement with European pharmaceutical partner company PharmaMar to market and distribute the novel oncology drug APLIDIN® (plitidepsin) in Australia and New Zealand. Under the terms of the agreement, PharmaMar will receive an upfront payment, royalties and additional remunerations
Cambridge, MA, and Melbourne, Australia, November 24, 2014: ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Specialised Therapeutics Australia Pty Ltd (STA), today announced the marketing approval of ICLUSIG™ (ponatinib) in Australia by the Therapeutic Goods Administration (TGA). The Australian Product Information for ICLUSIG states that it is indicated for the treatment of adult patients with: Chronic